This article is more than 5 years old. Information may no longer be current.
Five recent developments in cosmetic dermatology
Recent developments in cosmetic dermatology include the FDA clearance of Ulthera’s Cellfina System for long-term cellulite treatment and Health Canada’s approval of Kythera’s Belkyra for treating submental fat.
Other recent news on Healio.com/Dermatology included studies on the effects of Juvéderm Voluma:
FDA clears Cellfina System for cellulite treatment lasting 2 years
Ulthera announced that the FDA has cleared the Cellfina System for treatment of cellulite on the buttocks and thighs with results lasting at least 2 years.
The Cellfina System combines proprietary technology with subcision to treat the primary structural cause of cellulite, according to a press release. Read more
Health Canada approves Kythera's Belkyra for treating submental fat
Kythera Biopharmaceuticals announced that Health Canada has approved marketing of Belkyra (deoxycholic acid) for treating submental fat in adults.
Vince Bertucci
“Belkyra will provide my patients with a nonsurgical solution that can be tailored to their individual treatment goals for an improved chin profile,” Vince Bertucci, MD, FRCPC, president of the Canadian Dermatology Association, said in the release. Read more
Juvéderm Voluma effects in facial augmentation lasted up to 1 year
Juvéderm Voluma for facial revolumization produced results lasting up to a year in patients with little risk of adverse events, according to recently published study results.
Shannon Humphrey
Shannon Humphrey, MD, FRCPC, FAAD, and colleagues conducted a retrospective chart review of 2,342 patients who had facial augmentation with Juvéderm Voluma (hyaluronic acid 20 mg/mL smooth cohesive filler, Allergan) between Feb. 1, 2009, and Oct. 1, 2014. Read more
Researchers warn of rare risk for delayed nodules after Juvéderm Voluma injections
Although uncommon, researchers recommend physicians are aware of the risk for delayed nodules in patients after 3-D facial injections with Juvéderm Voluma, and have a management protocol in place, according to recent study results.
Researchers led by Katie Beleznay, MD, FRCPC, FAAD, of the department of dermatology and skin science at the University of British Columbia, conducted a retrospective chart review of patients who underwent 3-D facial injection with Juvéderm Voluma (hyaluronic acid gel, Allergan), a 20 mg/mL smooth cohesive filler, from Feb. 1, 2009 to Sept. 30, 2014. Read more
Half of consumers surveyed would consider cosmetic procedure, reports ASDS
The American Society for Dermatologic Surgery reported that half of recent survey participants would consider a cosmetic procedure.
George J. Hruza
“Continued advances in medical technology and the ever-growing track record of success for dermatologic surgeons combine to make pursuing an array of minimally invasive cosmetic medical procedures an increasingly comfortable decision for patients,” George J. Hruza, MD, MBA, ASDS president, said in the press release. Read more